Posted inClinical Updates news Respiratory Specialties
Camlipixant for Refractory Chronic Cough: Promising Phase 2b Trial Results and Clinical Implications
The SOOTHE phase 2b trial demonstrates that camlipixant, a P2X3 antagonist, significantly reduces cough frequency and improves quality of life in refractory chronic cough patients, with a favorable safety profile, supporting its potential as a new therapeutic option.